JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Matthew J. Schuchert
James D. Luketich
Rodney J. Landreneau
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Kilic, A.
Right arrow Articles by El-Hefnawy, T.
PubMed
Right arrow Articles by Kilic, A.
Right arrow Articles by El-Hefnawy, T.
Related Collections
Right arrow Esophagus - cancer

J Thorac Cardiovasc Surg 2008;136:199-204
© 2008 The American Association for Thoracic Surgery

General Thoracic Surgery

Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum

Arman Kilic, BSa, Matthew J. Schuchert, MDa, James D. Luketich, MDa, Rodney J. Landreneau, MDa, Anna E. Lokshin, PhDb, William L. Bigbee, PhDb, Talal El-Hefnawy, MD, PhDa,b,*

a Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa
b University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa

Received for publication July 15, 2007; revisions received December 3, 2007; accepted for publication January 15, 2008.

* Address for reprints: Talal El-Hefnawy, MD, PhD, Hillman Cancer Center, Research Pavilion 2.18b, 5117 Centre Ave, Pittsburgh, PA 15213 (Email: elhefnawyt{at}upmc.edu).

Objective: The aim of this study was to evaluate the feasibility of using novel autoantibody and cancer-related protein arrays to identify potential biomarkers for the early detection of esophageal adenocarcinoma in serum.

Methods: Sera from 18 patients with esophageal adenocarcinoma and 14 with gastroesophageal reflux disease were added to microarrays designed to detect circulating autoantibodies to 51 tumor-associated antigens. Sera from the same patients were also added to a 53-plex assay for various cancer-related proteins. Cutoff values at 3 standard deviations above the mean expression of gastroesophageal reflux disease were used as a boundary for positivity.

Results: Nine proteins and 11 autoantibodies were able to individually segregate at least 1 esophageal adenocarcinoma sample from gastroesophageal reflux disease by means of cutoff values. The most discriminative marker was Fas ligand in the protein array, which was associated with 83.3% sensitivity and 100% specificity. The best performing autoantibody, NY-ESO-1, detected 3 esophageal adenocarcinoma samples. When both of these markers were combined, a sensitivity of 88.9% and specificity of 100% were attained.

Conclusions: Cancer-related protein and autoantibody arrays provide a technically simple and rapid method of identifying potential biomarkers for the detection of esophageal adenocarcinoma in serum. Furthermore, combining these platforms improves the diagnostic power of either platform alone. Integrating technologies that detect the expression of multiple proteins and autoantibodies in serum may provide a noninvasive and accurate method of detecting early esophageal adenocarcinoma.

Abbreviations and Acronyms EAC = esophageal adenocarcinoma; FasL = Fas ligand; GERD = gastroesophageal reflux disease; TAA = tumor-associated antigen






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.